Thymosin Alpha-1 Research for Cancer Immunotherapy
An evidence-based overview of research examining Thymosin Alpha-1 in the context of cancer immunotherapy. This page synthesizes findings from peer-reviewed literature.
Research Summary
Thymosin Alpha-1 is used as a cancer immunotherapy adjuvant in multiple countries. Clinical trials have evaluated Ta1 as adjuvant therapy for hepatocellular carcinoma, non-small cell lung cancer, and melanoma. The peptide restores immune function that is often suppressed in cancer patients.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Thymosin Alpha-1 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.